Stealth Biotherapeutics

150 articles about Stealth Biotherapeutics

• Stealth BioTherapeutics to Present at BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference

  6/17/2020

  Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy , CEO, will participate in a fireside chat at the virtual BMO Capital Markets 2020 Prescripti

• Stealth BioTherapeutics to Present at Jefferies Virtual Healthcare Conference

  5/26/2020

  Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 4:30 p.m. ET.

• Stealth BioTherapeutics to Present at UBS Virtual Global Healthcare Conference

  5/13/2020

  Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy , CEO, will present at the UBS Virtual Global Healthcare Conference on Tuesday, May 19 at 12

• Stealth BioTherapeutics Reports First Quarter 2020 Financial Results and Recent Business Highlights

  5/7/2020

  Stealth BioTherapeutics Corp, a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, reported financial results for the first quarter ended March 31, 2020 and provided a corporate update.

• Stealth BioTherapeutics to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020

  5/4/2020

  Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will report first quarter 2020 financial results on Thursday, May 7, 2020, before the market opens.

• Stealth Biotherapeutics Announces $20 Million Financing to Advance Development of Elamipretide and Pipeline

  4/13/2020

  Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has completed a $20 million private placement with Morningside Venture (I) Investments Limited ("Mor

• Stealth BioTherapeutics Reports Fiscal Year 2019 Financial Results And Recent Business Highlights

  4/1/2020

  Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the year ended December 31, 2019 and announced recent business highlights.

• Stealth BioTherapeutics to Report Full Year 2019 Financial Results on Wednesday, April 1, 2020

  3/30/2020

  Stealth BioTherapeutics Corp today announced that it will report full year 2019 financial results on Wednesday, April 1, 2020 , before the market opens.

• FDA Grants Rare Pediatric Disease Designation to Stealth BioTherapeutics for Elamipretide for the Treatment of Barth Syndrome

  3/3/2020

  Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for elamipretide for the treatment of Barth syndrome, an ultra-rare genetic condition.

• Stealth BioTherapeutics to Present at 40th Annual Cowen Health Care Conference

  2/27/2020

  Stealth BioTherapeutics (NASDAQ: MITO), today announced that Reenie McCarthy , CEO, will present at the 40 th Annual Cowen Health Care Conference in Boston, MA on Wednesday, March 4.

• Stealth BioTherapeutics Announces Positive Results From Study to Evaluate Efficacy of Elamipretide in Barth Patients Compared to Natural History Control

  2/18/2020

  Stealth BioTherapeutics (Nasdaq: MITO), today announced positive results from its retrospective natural history study, clinical protocol SPIBA-001, evaluating the efficacy of subcutaneous injections of elamipretide relative to a natural history control comprised of 19 propensity score matched subjects with Barth syndrome (Barth)

• Stealth BioTherapeutics Initiates First-in-Human Study of SBT-272

  1/21/2020

  Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the initiation of a first-in-human Phase 1 trial evaluating its second generation pipeline compound, SBT-272, in healthy subjects.  

• 

  Job Cuts, Cancer Rates and Lawsuits: This Week's News Roundup

  1/10/2020

  As is often the case at the beginning and end of the year, a number of companies announced layoffs. Other news is related to lawsuits and an overall positive story about cancer death rates. Here’s a look.
• 

  Clinical Catch-Up: December 16-20

  12/23/2019

  Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look.

• Stealth BioTherapeutics Provides Update on Phase 3 Trial of Elamipretide in Primary Mitochondrial Myopathy

  12/20/2019

  Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced top-line data from the Phase 3 MMPOWER-3 trial evaluating elamipretide for treatment of patients with primary mitochondrial myopathy (PMM).

• 

  Stealth Bio Faces Setback in Failed Mitochondrial Disease Trial

  12/20/2019

  Boston-based Stealth BioTherapeutics reported that its Phase III MMPOWER-3 clinical trial of elamipetride failed to meet its primary endpoint.

• Stealth Biotherapeutics to Present at Jefferies 2019 London Healthcare Conference

  11/19/2019

  Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the Jefferies 2019 London Healthcare Conference in London, UK, on Wednesday, November 20, 2019 at 8:00 am GMT.

• Stealth BioTherapeutics Reports Third Quarter 2019 Financial Results And Recent Business Highlights

  11/14/2019

  Stealth BioTherapeutics Corp. reported financial results for the third quarter ended September 30, 2019 and provided a corporate update.

• Stealth Biotherapeutics to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019

  11/11/2019

  Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will report third quarter 2019 financial results on Thursday, November 14, 2019, before the market opens.

• Stealth BioTherapeutics Presents Data for Elamipretide on Cardiac Function in Barth Syndrome

  10/17/2019

  Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the presentation of new data from the open-label extension portion of the Phase 2/3 TAZPOWER study evaluating elamipretide in patients with Barth syndrome